DELCATH SYSTEMS INC (DCTH)

US24661P8077 - Common Stock

4.77  -0.32 (-6.29%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

DELCATH SYSTEMS INC

NASDAQ:DCTH (3/28/2024, 8:04:35 PM)

4.77

-0.32 (-6.29%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap109.33M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

DCTH Daily chart

Company Profile

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 52 full-time employees. The company went IPO on 2000-10-19. The firm is focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.

Company Info

DELCATH SYSTEMS INC

1633 Broadway Ste 22C

New York City NEW YORK 10019

P: 12124892100

CEO: Gerard Michel

Employees: 52

Website: https://delcath.com/

DCTH News

News Image3 days ago - InvestorPlaceDCTH Stock Earnings: Delcath Systems Beats EPS, Misses Revenue for Q4 2023

DCTH stock results show that Delcath Systems beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

News Image3 days ago - BusinessInsiderDCTH Stock Earnings: Delcath Systems Beats EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Delcath Systems (NASDAQ:DCTH) just reported results for the fourth quarter of 2...

News Image3 days ago - Delcath Systems, Inc.Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and...

News Image7 days ago - Market News VideoFriday 3/22 Insider Buying Report: DCTH, ARWR
News Image9 days ago - Delcath Systems, Inc.Delcath Systems Closes $7 Million Private Placement

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

News Image11 days ago - Delcath Systems, Inc.Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...

DCTH Twits

Here you can normally see the latest stock twits on DCTH, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example